Raajit Rampal, MD
Enriched profileDirector, Center for Hematologic Malignancies and Director, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center
Raajit Rampal is Director, Center for Hematologic Malignancies and Director, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 594 publications with 12,454 citations (h-index 60); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Raajit Rampal, MD, is Director, Center for Hematologic Malignancies and Director, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center. The public record shows 594 publications with 12,454 citations (h-index 60), centered on Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 23 companies, 4 NIH-funded awards (2014–2026).
- Most recent indexed publication: 2026 · Leukemia
- Top research focus: Acute Myeloid Leukemia Research
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 23 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 17 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 154.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 18 Oct 2026
23 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20257 payments$41,161openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year202517 payments$22,691openpaymentsdata.cms.gov ↗
- Incyte CorporationProgram year202520 payments$21,348openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Jakafi100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
4 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
- Core D: Biomarker and Bio-Informatics Core
Icahn School of Medicine at Mount Sinai
FY2026$624,089P01CA108671 - Evaluation of genetic and epigenetic determinants of response in patients with accelerated and blast phase Myeloproliferative Neoplasm (MPNs)
Sloan-Kettering Inst Can Research
FY2026$444,590R21CA313410 - Core D: Biomarker and Bio-Informatics Core
Icahn School of Medicine at Mount Sinai
FY2025$624,089P01CA108671
Congress activity
Updated 18 Oct 2026
129 congress contributions (2014–2026) across AACR, ASCO, ASH, ESMO per OpenAlex. The most recent:
- Abstract B040: Understanding and Overcoming RAS-pathway Mediated Therapeutic Resistance and Disease Progression in Myeloproliferative Neoplasms
AACR Annual Meeting
AACR2026Co-author - RALLY-MF: Initial efficacy of a phase 2 study of DISC-0974, an anti-hemojuvelin antibody, to treat anemia in myelofibrosis.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.
Nature medicine
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01
- 02Single-cell mutation analysis of clonal evolution in myeloid malignanciesArticle507 citations2020
- 03
- 04Efficacy of MEK inhibition in patients with histiocytic neoplasmsArticle395 citations2019
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/raajit-rampal-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
treating-blood-cancers.podcast.show/episode/60920721
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →treating-blood-cancers.podcast.show ↗ - Other
mpnresearchfoundation.org/raajit-rampal-md-phd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mpnresearchfoundation.org ↗ - Other
mskcc.org/videos/meet-raajit-rampal-leukemia-specialist-at-msk
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
PhD (molecular and cellular biology), Stony Brook University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mpnresearchfoundation.org ↗ - Board certified: Internal Medicine
Medical Oncology, Hematology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Editorial & leadership roles
journal and society appointments- Medical Advisor
MPN Research Foundation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mpnresearchfoundation.org ↗
Secondary affiliations
appointments beyond the home institution- Medical Advisor
MPN Research Foundation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mpnresearchfoundation.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center